Literature DB >> 17287300

Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension.

Jay Suntharalingam1, Rajiv D Machado, Linda D Sharples, Mark R Toshner, Karen K Sheares, Rodney J Hughes, David P Jenkins, Richard C Trembath, Nicholas W Morrell, Joanna Pepke-Zaba.   

Abstract

BACKGROUND: Although pulmonary endarterectomy (PEA) is potentially curative in chronic thromboembolic pulmonary hypertension (CTEPH), some patients have distally distributed disease that is not amenable to surgery. The aetiology and characteristics of this patient group are currently not well understood.
OBJECTIVES: This study compares the baseline demographic features and outcomes in subjects with distal CTEPH, those with proximal CTEPH and those with idiopathic pulmonary arterial hypertension (IPAH) to determine whether these conditions represent separate entities or whether they exist along the same spectrum of disease.
METHODS: The medical history, clinical characteristics, bone morphogenetic protein receptor type II (BMPR2) mutation status and outcomes of 96 subjects with IPAH, 35 with distal CTEPH and 68 with proximal CTEPH referred to a single specialist centre between 1994 and 2005 were reviewed.
RESULTS: There were significant differences between the distal CTEPH, proximal CTEPH and IPAH groups in age (55.9 years vs 54.8 years vs 46.2 years, p<0.001), proportion who were male (43% vs 69% vs 29%, p<0.001), previous deep vein thrombosis (28.6% vs 30.9% vs 3.1%, p<0.001), positive BMPR2 status (0% vs 0% vs 15%, p = 0.018), mean pulmonary artery pressure (47.3 mm Hg vs 45.4 mm Hg vs 54.8 mm Hg, p<0.001) and total pulmonary resistance (12.9 WU vs 12.4 WU vs 18.1 WU, p<0.001). Patients with distal CTEPH and those with IPAH were managed similarly and had comparable survival characteristics (1 year survival 77% vs 86%; 3 year survival 53% vs 60%; p = 0.68).
CONCLUSIONS: Patients with distal CTEPH share certain demographic features with patients with proximal CTEPH that not only indicate a common aetiology but also help to differentiate them from patients with IPAH. Despite more favourable haemodynamic parameters in those with distal CTEPH, patients in this group had a poor long-term outcome which was similar to that of patients with IPAH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17287300      PMCID: PMC2117254          DOI: 10.1136/thx.2006.070680

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  39 in total

1.  The natural history of acute and chronic thromboembolic disease: the search for the missing link.

Authors:  P F Fedullo; L J Rubin; K M Kerr; W R Auger; R N Channick
Journal:  Eur Respir J       Date:  2000-03       Impact factor: 16.671

Review 2.  State-of-the-art imaging techniques in chronic thromboembolic pulmonary hypertension.

Authors:  Richard Coulden
Journal:  Proc Am Thorac Soc       Date:  2006-09

3.  Prognostic factors in medically treated patients with chronic pulmonary embolism.

Authors:  J Lewczuk; P Piszko; J Jagas; A Porada; S Wójciak; B Sobkowicz; K Wrabec
Journal:  Chest       Date:  2001-03       Impact factor: 9.410

4.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

Authors:  J H Newman; L Wheeler; K B Lane; E Loyd; R Gaddipati; J A Phillips; J E Loyd
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

5.  BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.

Authors:  R D Machado; M W Pauciulo; J R Thomson; K B Lane; N V Morgan; L Wheeler; J A Phillips; J Newman; D Williams; N Galiè; A Manes; K McNeil; M Yacoub; G Mikhail; P Rogers; P Corris; M Humbert; D Donnai; G Martensson; L Tranebjaerg; J E Loyd; R C Trembath; W C Nichols
Journal:  Am J Hum Genet       Date:  2000-12-12       Impact factor: 11.025

6.  Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

Authors:  Hossein Ardeschir Ghofrani; Ralph Wiedemann; Frank Rose; Horst Olschewski; Ralph Theo Schermuly; Norbert Weissmann; Werner Seeger; Friedrich Grimminger
Journal:  Ann Intern Med       Date:  2002-04-02       Impact factor: 25.391

7.  Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension.

Authors:  L H Steenhuis; H J Groen; G H Koëter; T W van der Mark
Journal:  Eur Respir J       Date:  2000-08       Impact factor: 16.671

8.  Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.

Authors:  J R Thomson; R D Machado; M W Pauciulo; N V Morgan; M Humbert; G C Elliott; K Ward; M Yacoub; G Mikhail; P Rogers; J Newman; L Wheeler; T Higenbottam; J S Gibbs; J Egan; A Crozier; A Peacock; R Allcock; P Corris; J E Loyd; R C Trembath; W C Nichols
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

9.  Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy.

Authors:  Patricia A Thistlethwaite; Makato Mo; Michael M Madani; Reena Deutsch; Daniel Blanchard; David P Kapelanski; Stuart W Jamieson
Journal:  J Thorac Cardiovasc Surg       Date:  2002-12       Impact factor: 5.209

10.  BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives.

Authors:  M Humbert; Z Deng; G Simonneau; R J Barst; O Sitbon; M Wolf; N Cuervo; K J Moore; S E Hodge; J A Knowles; J H Morse
Journal:  Eur Respir J       Date:  2002-09       Impact factor: 16.671

View more
  8 in total

Review 1.  The genetics of pulmonary arterial hypertension.

Authors:  Eric D Austin; James E Loyd
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

2.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

Review 3.  Vascular complications after splenectomy for hematologic disorders.

Authors:  Shelley E Crary; George R Buchanan
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

4.  The actuarial survival analysis of the surgical and non-surgical therapy regimen for chronic thromboembolic pulmonary hypertension.

Authors:  Hui-Li Gan; Jian-Qun Zhang; Ping Bo; Qi-Wen Zhou; Sheng-Xun Wang
Journal:  J Thromb Thrombolysis       Date:  2009-04-11       Impact factor: 2.300

5.  The genetics of pulmonary arterial hypertension in the post-BMPR2 era.

Authors:  Joshua P Fessel; James E Loyd; Eric D Austin
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017

6.  Factors predicting outcome after pulmonary endarterectomy.

Authors:  Cécile Tromeur; Xavier Jaïs; Olaf Mercier; Francis Couturaud; David Montani; Laurent Savale; Mitja Jevnikar; Jason Weatherald; Olivier Sitbon; Florence Parent; Dominique Fabre; Sacha Mussot; Philippe Dartevelle; Marc Humbert; Gérald Simonneau; Elie Fadel
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

7.  Social deprivation in Scottish populations with pulmonary hypertension secondary to connective tissue disease and chronic thromboembolic disease.

Authors:  Michael McGettrick; Paul McCaughey; Alexander MacLellan; Melanie Brewis; A Colin Church; Martin K Johnson
Journal:  ERJ Open Res       Date:  2020-11-10

8.  Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension-A Genetic Study.

Authors:  Christina A Eichstaedt; Jeremias Verweyen; Michael Halank; Nicola Benjamin; Christine Fischer; Eckhard Mayer; Stefan Guth; Christoph B Wiedenroth; Benjamin Egenlauf; Satenik Harutyunova; Panagiota Xanthouli; Alberto M Marra; Heinrike Wilkens; Ralf Ewert; Katrin Hinderhofer; Ekkehard Grünig
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.